Top Research Reports for Microsoft, Amazon.com & Eli Lilly

18.11.25 22:12 Uhr

Werte in diesem Artikel
Aktien

189,08 EUR 0,68 EUR 0,36%

905,00 EUR 5,20 EUR 0,58%

414,00 EUR -1,10 EUR -0,27%

Indizes

PKT PKT

45.752,3 PKT -386,5 PKT -0,84%

24.054,4 PKT -586,1 PKT -2,38%

22.078,1 PKT -486,2 PKT -2,15%

17.603,7 PKT -150,0 PKT -0,84%

3.290,2 PKT -51,5 PKT -1,54%

6.538,8 PKT -103,4 PKT -1,56%

Tuesday, November 18, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), Amazon.com, Inc. (AMZN) and Eli Lilly and Co. (LLY). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Pre-markets Stay Red Ahead of NVIDIA Earnings, Jobs DataToday's Featured Research ReportsMicrosoft’s shares have outperformed the Zacks Computer - Software industry over the year-to-date period (+17.8% vs. +13.3%). The company’s fiscal first-quarter 20256 results demonstrate robust fundamental strength, with earnings and revenue exceeding expectations driven by cloud and AI business momentum alongside Copilot adoption. Azure's 40% growth and $392 billion commercial remaining performance obligation signal sustained demand, while diversified revenue streams across productivity software, cloud infrastructure, and gaming provide stability. The expanded OpenAI partnership securing $250 billion in additional Azure commitments reinforces long-term AI leadership. The Zacks analyst expect’s fiscal 2026 net sales to grow 15.1% from fiscal 2025. However, capacity constraints through fiscal year-end limit immediate revenue capture despite strong demand. Management's guidance for flat operating margins and continued infrastructure investments indicate profitability headwinds.(You can read the full research report on Microsoft here >>>)Shares of Amazon.com have gained +2.6% over the year-to-date period against the Zacks Internet - Commerce industry’s gain of +10.1%. The company reported strong third-quarter results earnings of $1.95 per share beating estimates by 23% and revenue of $180.1 billion growing 13.4% year-over-year. AWS revenue rose 20.2% to $33 billion, though lagging competitors' cloud growth rates of 34-40%. Amazon demonstrated pricing power through 24% advertising revenue growth and robust Prime engagement. AI initiatives like Trainium2 show promise and Q4 guidance projects 10-13% sales growth. The Zacks analyst expect’s 2025 net sales to grow 10.6% from 2024. However, profitability concerns emerged as operating income remained flat at $17.4 billion, impacted by $4.3 billion in special charges. Free cash flow declined sharply to $14.8 billion from $47.7 billion due to aggressive $50.9 billion AI infrastructure investments. Elevated operating expenses and stiff cloud competition are headwinds.(You can read the full research report on Amazon.com here >>>)Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+33.4% vs. +16.8%). The company’s Q3 earnings and sales beat estimates. Demand for popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them the company’s key top-line drivers. Launches of these drugs in new international markets and improved supply from ramped-up production have led to strong year-to-date sales in 2025. Lilly’s other new drugs like Kisunla, Omvoh and Jaypirca are also contributing to its top-line growth. Lilly is also making rapid pipeline progress in obesity and diabetes with oral GLP-1 obesity pill, orforglipron, expected to be launched next year. Declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds. (You can read the full research report on Eli Lilly here >>>)Other noteworthy reports we are featuring today include The Charles Schwab Corp. (SCHW), Canadian Natural Resources Ltd. (CNQ) and Yum! Brands, Inc. (YUM).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadAdoption of Cloud and Office 365 Strength Aid Microsoft (MSFT)Amazon (AMZN) Rides on Prime and AWS Amid Rising CompetitionLilly (LLY) New Drugs to Drive Sales Growth Amid Rising CompetitionFeatured ReportsStrategic Acquisitions Aid Schwab (SCHW) Amid Cost ConcernsPer the Zacks analyst, while Schwab's inorganic growth initiatives and other revenue diversification efforts will aid profits, it might lead to higher costs, thus hurting the bottom line to an extent.Yum! Brands (YUM) Banks on Digital Efforts, High Costs HurtPer the Zacks analyst, Yum! Brands is likely to benefit from its enhanced digital capabilities, Byte platform and unit expansion efforts. However, high costs and macro woes ail.Humana's (HUM) Solid Medicaid Business Aids, High Costs AilPer the Zacks Analyst, Humana's robust Medicaid business will help it expand the Retail portfolio, in turn boosting top-line growth. Yet, escalating expenses continue to weigh on margins.Brown and Brown (BRO) Gains on Acquisitions, Cost Woes LingerPer the Zacks analyst, Brown and Brown is set to grow on strategic acquisitions and mergers, which enhance its capabilities. However, escalating expenses drag margin expansion.Smart Water Innovation and Buyouts Fuel Badger Meter's (BMI) ProspectsPer the Zacks analyst, Badger Meter's performance is driven by its customer-focused innovation and strategic agility. Strategic acquisitions play a key role in expanding its business operations.PBF Energy's (PBF) High-Complexity, Diversified Refining Network AidsPBF's diversified refining network, with complex refining systems, should support the production of superior-grade refined products. However, rising compliance costs concern the Zacks analyst.Focus on R and D Aids Inspire Medical (INSP) Amid Rising ExpensesThe Zacks analyst is upbeat about Inspire Medical's focus on driving innovation and improving patient lives via research and development or R and D despite its escalating operating expenses.New UpgradesCanadian Natural (CNQ) to Gain from Completion of AOSP Swap With ShellThe Zacks analyst believes Canadian Natural's 100% ownership in Athabasca Oil Sands project (AOSP) will add about 31,000 bbl/d of zero-decline bitumen boosting long-term cash flow.Macy's (M) Pursues Bold New Chapter to Accelerate Long-Term GrowthPer the Zacks analyst, Macy's Bold New Chapter strategy is gaining traction, with brand elevation, luxury expansion, and operational modernization supporting sustained profitability.Alkermes (ALKS) Rides on Robust Sales Performance of Proprietary DrugsPer the Zacks analyst, Alkermes' top line is being driven by the sales of its proprietary drugs, Vivitrol, Aristada and Lybalvi. The company is also making good progress with its pipeline developmentNew DowngradesKnight-Swift (KNX) to Face Pressure from Elevated ExpensesPer the Zacks analyst, the company is likely to encounter increased pressure from high leverage, rising costs, and ongoing driver shortages in the trucking industry.Tariff and Macro Economic Uncertainty Ail Harley-Davidson (HOG)Tariffs are squeezing gross margins, while weak consumer confidence, high rates and inflation are limiting retail demand keeping the Zacks analyst bearish on the stock.Weaker Prices, India Business Exit Ail FMC Corp (FMC)Per the Zacks analyst, FMC faces near-term revenue pressure from the removal of the India business. Weaker prices will also weigh on its margins. nZacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Yum! Brands, Inc. (YUM): Free Stock Analysis Report The Charles Schwab Corporation (SCHW): Free Stock Analysis Report Canadian Natural Resources Limited (CNQ): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Amazon und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Amazon

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Amazon

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Amazon

Wer­bung

Analysen zu Amazon

DatumRatingAnalyst
31.10.2025Amazon KaufenDZ BANK
31.10.2025Amazon BuyUBS AG
31.10.2025Amazon OutperformRBC Capital Markets
31.10.2025Amazon OverweightJP Morgan Chase & Co.
31.10.2025Amazon OutperformRBC Capital Markets
DatumRatingAnalyst
31.10.2025Amazon KaufenDZ BANK
31.10.2025Amazon BuyUBS AG
31.10.2025Amazon OutperformRBC Capital Markets
31.10.2025Amazon OverweightJP Morgan Chase & Co.
31.10.2025Amazon OutperformRBC Capital Markets
DatumRatingAnalyst
26.09.2018Amazon HoldMorningstar
30.07.2018Amazon neutralJMP Securities LLC
13.06.2018Amazon HoldMorningstar
02.05.2018Amazon HoldMorningstar
02.02.2018Amazon neutralJMP Securities LLC
DatumRatingAnalyst
11.04.2017Whole Foods Market SellStandpoint Research
23.03.2017Whole Foods Market SellUBS AG
14.08.2015Whole Foods Market SellPivotal Research Group
04.02.2009Amazon.com sellStanford Financial Group, Inc.
26.11.2008Amazon.com ErsteinschätzungStanford Financial Group, Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Amazon nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen